Oragenics, Inc. — FY2011 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2011, including fourth-quarter results. Oragenics shifted its focus toward oral-care probiotics for people and companion animals, led by its commercial ProBiora3 ingredient and Evora-branded products. Its other programs—LPT3-04 for weight management, SMaRT tooth-decay replacement therapy, and MU1140-S antibiotics—remain at development stages. The filing was signed April 16, 2012.
Financial performance and position
| Metric | FY2011 | FY2010 |
|---|---|---|
| Net revenue | $1.444 million | $1.309 million |
| ProBiora3 product sales | $1.230 million | $1.129 million |
| Cost of sales | $714,000 | $912,000 |
| Research and development | $2.449 million | $2.015 million |
| Selling, general and administrative | $5.628 million | $6.285 million |
| Operating loss | $7.346 million | $7.903 million |
| Net loss | $7.679 million | $7.805 million |
| Basic and diluted loss per share | $1.34 | $1.42 |
| Cash used in operating activities | $5.495 million | $6.448 million |
- FY2011 revenue increased about 10%; product sales rose while grant revenue also contributed. Gross profit was approximately $731,000, or 50.6% of revenue, compared with approximately $397,000, or 30.3%, in FY2010. Lower scrap and inventory-reserve expense was a major factor in the cost-of-sales decline.
- Fourth-quarter 2011 revenue was $396,590 versus $298,157 in Q4 2010; net loss was $1.939 million versus $2.173 million. R&D increased to $842,191 from $641,536, while SG&A decreased to $1.214 million from $1.493 million.
- At year-end, cash and cash equivalents were $171,739, restricted cash was $264,960, and current assets totaled $1.118 million. Current liabilities were $9.446 million, including $7.5 million of current convertible revolving debt to the company’s largest shareholder. Working capital deficit was $8.328 million; shareholders’ deficit was $8.179 million.
- Year-end total assets were $1.267 million and accumulated deficit was $40.996 million. The company reported no investing cash outflow in 2011 and $5.534 million of financing cash inflow, principally from shareholder borrowings and release of restricted cash.
- The filing reports no operating margin improvement to profitability: operating and net losses continued, and the company had no material product revenue source other than ProBiora3 sales. No cash dividends were paid or anticipated.
Changes, outlook, and risks
- Management left mass retail during Q1 2011, citing limited capital, and redirected sales efforts to direct-to-consumer, dental professionals, private label and international distribution. ProBiora3 sales grew modestly; management said future revenue growth depended on distribution and marketing execution.
- Management expected the second Phase 1 SMaRT trial to conclude in the second half of 2012, subject to progress and funding. LPT3-04’s 12-week placebo-controlled trial showed statistically significant weight loss, according to the company; it was seeking a development partner. MU1140-S production scale-up and preclinical work were planned for 2012, dependent on capital.
- Management said existing cash, available borrowing under the new KFLP loan and grant proceeds were expected to fund operations only through June 2012. The auditor’s report raised substantial doubt about the company’s ability to continue as a going concern. Additional financing was not assured; absent funding, the company could curtail or cease operations.
- After year-end, in March 2012, the company exchanged $8.737 million of KFLP debt and accrued interest for 6,285,619 shares and warrants for 1,571,405 shares, terminating the revolving facility. It also entered a secured loan agreement for up to $2.5 million, at 5% interest, with a three-year maturity and collateral over selected assets relating to its core technologies. A qualified equity financing of at least $5 million triggers automatic conversion. The transactions materially increased dilution and KFLP control; the filing reported KFLP-family beneficial ownership of approximately 81.5% as of April 2012.
- Key risks include very limited liquidity, dependence on the controlling shareholder for financing, potential loss of pledged intellectual property if secured debt cannot be repaid, dilution, FDA and clinical-trial uncertainty, reliance on partners and contract manufacturers, and uncertain commercial adoption. The non-attenuated SMaRT IND remained on clinical hold.
- Management concluded that disclosure controls and internal control over financial reporting were not effective at year-end. Unremediated material weaknesses included limited control documentation, inadequate segregation of duties, and lack of formal written accounting and SEC-reporting procedures.
- The company reported no material legal proceedings. Its UFRF licenses require $1 million annually in combined research and development spending and quarterly minimum royalties; failure to meet obligations could jeopardize the licenses. Texas A&M license milestones also carry potential payments and termination provisions.
Investor facts to verify
- Whether the additional KFLP loan advance was funded and whether financing after June 2012 was secured.
- Cash runway, operating cash burn, and the status of the going-concern qualification.
- Fully diluted share count and the effects of the debt conversion, warrants, options, and future financing.
- ProBiora3 sales, gross margin, repeat purchasing, returns, and progress in dental, private-label and international channels.
- Results and timing of the SMaRT trial and FDA discussions, LPT3-04 partnering, and MU1140-S scale-up and preclinical work.
- Progress in remediating internal-control weaknesses and continued compliance with UFRF and Texas A&M license terms.